Dipeptidyl peptidase 4 inhibition stimulates distal tubular natriuresis and increases in circulating sdf-1a1-67 in patients with type 2 diabetes

Diabetes Care

Volumn 40, Issue 8, 2017, Pages 1073-1081

  Lovshin, Julie A ^a,b   Rajasekeran, Harindra ^a   Lytvyn, Yulyia ^a   Lovblom, Leif E ^c   Khan, Shajiha ^a   Alemu, Robel ^a   Locke, Amy ^a   Lai, Vesta ^a   He, Huaibing ^d   Hittle, Lucinda ^d   Wang, Weixun ^d   Drucker, Daniel J ^b,c   Cherney, David Z I ^a,b  

^a UNIVERSITY HEALTH NETWORK   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c MOUNT SINAI HOSPITAL   (Canada)

^d MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDIABETIC AGENT; CXCL12 PROTEIN, HUMAN; DIPEPTIDYL PEPTIDASE IV INHIBITOR; SITAGLIPTIN; SLC5A2 PROTEIN, HUMAN; SODIUM GLUCOSE COTRANSPORTER 2; STROMAL CELL DERIVED FACTOR 1;

AGED; ANTAGONISTS AND INHIBITORS; BLOOD; BLOOD PRESSURE; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECTS; FEMALE; HEMODYNAMICS; HUMAN; KIDNEY; MALE; METABOLISM; MIDDLE AGED; NATRIURESIS; NON INSULIN DEPENDENT DIABETES MELLITUS; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL;

AGED; BLOOD PRESSURE; CHEMOKINE CXCL12; DIABETES MELLITUS, TYPE 2; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; DOUBLE-BLIND METHOD; FEMALE; HEMODYNAMICS; HUMANS; HYPOGLYCEMIC AGENTS; KIDNEY; MALE; MIDDLE AGED; NATRIURESIS; PROSPECTIVE STUDIES; SITAGLIPTIN PHOSPHATE; SODIUM-GLUCOSE TRANSPORTER 2;

EID: 85028082197     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc17-0061     Document Type: Article

References (28)

1. Cornel JH, Bakris GL, Stevens SR, et al.; TECOS Study Group. Effect of sitagliptin on kidney function and respective cardiovascular outcomes in type 2 diabetes: outcomes from TECOS. Diabetes Care 2016;39:2304-2310
2. Turner LW, Nartey D, Stafford RS, Singh S, Alexander GC. Ambulatory treatment of type 2 diabetes in the U.S., 1997-2012. Diabetes Care 2014;37:985-992
3. Lovshin JA, Drucker DJ. Incretin-based therapies for type 2 diabetes mellitus. Nat Rev Endocrinol 2009;5:262-269
4. Mulvihill EE, Drucker DJ. Pharmacology, physiology, and mechanisms of action of dipeptidyl peptidase-4 inhibitors. Endocr Rev 2014;35:992-1019
5. Green JB, Bethel MA, Armstrong PW, et al.; TECOS Study Group. Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes. N Engl J Med 2015;373:232-242
6. White WB, Cannon CP, Heller SR, et al.; EXAMINE Investigators. Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med 2013;369:1327-1335
7. Scirica BM, Bhatt DL, Braunwald E, et al.; SAVOR-TIMI 53 Steering Committee and Investigators. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med 2013;369:1317-1326
8. U.S. Food and Drug Administration. FDA Drug and Safety Communication: FDA adds warnings about heart failure risk to labels of type 2 diabetes medicines containing saxagliptin and alogliptin, 2016. Available from https://www.fda.gov/ Drugs/DrugSafety/ucm486096.htm. Accessed 12 May 2017
9. Zinman B, Lachin JM, Inzucchi SE. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 2016;374:1092-1094
10. Tonneijck L, Smits MM, Muskiet MH, et al. Renal effects of DPP-4 inhibitor sitagliptin or GLP-1 receptor agonist liraglutide in overweight patients with type 2 diabetes: a 12-week, randomized, double-blind, placebo-controlled trial. Diabetes Care 2016;39:2042-2050
11. Schnurr E, Lahme W, Küppers H. Measurement of renal clearance of inulin and PAH in the steady statewithout urine collection. ClinNephrol 1980;13:26-29
12. Cherney DZI, Perkins BA, Soleymanlou N, et al. Renal hemodynamic effect of sodiumglucose cotransporter 2 inhibition in patients with type 1 diabetes mellitus. Circulation 2014; 129:587-597
13. Gomez DM. Evaluation of renal resistances, with special reference to changes in essential hypertension. J Clin Invest 1951;30:1143-1155
14. Bjornstad P, ?Skrtić M, Lytvyn Y, Maahs DM, Johnson RJ, Cherney DZ. The Gomez equations and renal hemodynamic function in kidney disease research. Am J Physiol Renal Physiol 2016; 311:F967-F975.
15. Cherney DZ, Reich HN, Scholey JW, et al. The effect of aliskiren on urinary cytokine/chemokine responses to clamped hyperglycaemia in type 1 diabetes. Diabetologia 2013;56:2308-2317
16. Lovshin JA, Barnie A, DeAlmeida A, Logan A, Zinman B, Drucker DJ. Liraglutide promotes natriuresis but does not increase circulating levels of atrial natriuretic peptide in hypertensive subjects with type 2 diabetes. Diabetes Care 2015;38:132-139
17. Cherney DZ, Reich HN, Jiang S, et al. Hyperfiltration and effect of nitric oxide inhibition on renal and endothelial function in humans with uncomplicated type 1 diabetes mellitus. Am J Physiol Regul Integr Comp Physiol 2012;303: R710-R718
18. Wang W, Choi BK, Li W, et al. Quantification of intact and truncated stromal cell-derived factor-1a in circulation by immunoaffinity enrichment and tandem mass spectrometry. J Am Soc Mass Spectrom 2014;25:614-625
19. Zeng W, Xu Y, Constanzer M, Woolf EJ. Determination of sitagliptin in human plasma using protein precipitation and tandemmass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 2010;878:1817-1823
20. Rieg T, Gerasimova M, Murray F, et al. Natriuretic effect by exendin-4, but not the DPP-4 inhibitor alogliptin, is mediated via the GLP-1 receptor and preserved in obese type 2 diabetic mice. Am J Physiol Renal Physiol 2012;303:F963-F971
21. Anders HJ, Davis JM, Thurau K. Nephron protection in diabetic kidney disease. N Engl J Med 2016;375:2096-2098
22. Perkins BA, Udell JA, Cherney DZ. No need to sugarcoat the message: is cardiovascular risk reduction from SGLT2 inhibition related to natriuresis? Am J Kidney Dis 2016;68:349-352
23. Takashima S, Fujita H, Fujishima H, et al. Stromal cell-derived factor-1 is upregulated by dipeptidyl peptidase-4 inhibition and has protective roles in progressive diabetic nephropathy. Kidney Int 2016;90:783-796
24. Heerspink HJ, Perkins BA, Fitchett DH, Husain M, Cherney DZ. Sodium glucose cotransporter 2 inhibitors in the treatment of diabetes mellitus: cardiovascular and kidney effects, potential mechanisms, and clinical applications. Circulation 2016;134:752-772
25. Marso SP, Daniels GH, Brown-Frandsen K, et al.; LEADER Steering Committee; LEADER Trial Investigators. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med 2016;375:311-322
26. Chen LH,Advani SL, Thai K, et al. SDF-1/CXCR4 signaling preservesmicrovascular integrity and renal function in chronic kidney disease. PLoS One 2014;9:e92227
27. Navarro-González JF, Mora-Fernández C. The role of inflammatory cytokines in diabetic nephropathy. J Am Soc Nephrol 2008;19:433-442
28. Makdissi A, Ghanim H, VoraM, et al. Sitagliptin exerts an antinflammatory action. J Clin Endocrinol Metab 2012;97:3333-3341